Sanara MedTech Inc. has recently achieved a significant turnaround in operating profitability following its strategic exit from the loss-making Tissue Health Plus (THP) program. By concentrating resources exclusively on its surgical portfolio—primarily soft tissue repair and bone fusion products—the company leveraged contract manufacturing efficiencies to improve margins, increasing operating income from a loss position to $7.3 million in 2025. Despite the operating income rebound and stronger cash flow, net losses deepened due to non-operating factors. The company faces risks from supplier concentration and competitive pressures as it advances pipeline innovations such as the OsStic BioAdhesive. Monitoring execution and adoption of new surgical technologies will be critical to sustaining growth.